The company filed a shelf registration for $1.47 billion in common stock linked to an employee ownership plan. It is expanding in private credit and energy infrastructure, completing a hydrogen-capable power plant and exploring an investment in VoltaGrid. Its Life Sciences division announced a funding agreement for an acute leukemia treatment. It finalized the acquisition of Champions Group and is considering selling its clinical trials business. Despite these strategic moves, the CEO's high compensation coincided with the stock underperforming the S&P 500.